89bio (ETNB) Stock Highlights

7.94 | +12.94%

2024-12-21 04:26:11

89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Statistics

Range Today

6.6 7.95

Volume Today 4.5M

Range 1 Year

6.43 16.63

Volume 1 Year 244.29M

Range 3 Year

2 22.93

Volume 3 Year 794.93M

Range 10 Year

2 47.253

Volume 10 Year 853.58M

Highlights

Market Capitalization 1.11B (small)

Floating Shares 68.09M

Current Price 7.94

Price To Earnings -4.64

Price To Book 2.93

Earnings Per Share -2.06

Payout Ratio 0%

Performance

Latest +12.94%

1 Month -1.61%

3 Months -4.22%

6 Months -5.02%

1 Year -26.55%

3 Years -32.48%

5 Years -68.92%

10 Years -60.3%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.